StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

BioXcel Therapeutics's price to sales ratio was 1.1× on Oct 19, 2026, against 15.6× a year earlier. Over the last 3 years it ranged from 1.1× to 113.2×, with a median of 30.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Oct 19, 20261.1×−41.5
2025Dec 31, 202542.5×+35.6
2024Dec 31, 20247.0×−62.6
2023Dec 29, 202369.5×–

More BioXcel Therapeutics figures

See a number that looks wrong?